Eterna Therapeutics Reports Positive Preclinical Results for Cancer Therapy ERNA-101; Shares Jump

MT Newswires Live

Jan 14

Eterna Therapeutics' (ERNA) shares nearly doubled in early trading on Tuesday after the company reported positive results from a preclinical study of its lead cell therapy product ERNA-101

Eterna said the proof-of-concept study demonstrated "massive" T cell infiltration after only one dose, with reduced tumor burden and extended survival in mice with ovarian cancer.

By changing the tumor microenvironment from having low immune activity to an active immune environment, ERNA-101 "may not only lead to improved therapeutic outcomes as a monotherapy but is also anticipated to significantly enhance the efficacy of CAR-T and CAR-NK cell therapies in the future," the company said.

Regarding safety, body weight distribution showed no significant difference between the ERNA-101 and control groups, Eterna said.

Price: 0.4959, Change: +0.19, Percent Change: +60.49

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503571945"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503571945\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503571945?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 22:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503571945","market":"sh","top_or_hot":-1,"title":"Eterna Therapeutics Reports Positive Preclinical Results for Cancer Therapy ERNA-101; Shares Jump","media":"MT Newswires Live","content":"<html><body><p> Eterna <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (ERNA) shares nearly doubled in early trading on Tuesday after the company reported positive results from a preclinical study of its lead cell therapy product ERNA-101</p><p>Eterna said the proof-of-concept study demonstrated \"massive\" T cell infiltration after only one dose, with reduced tumor burden and extended survival in mice with ovarian cancer.</p><p>By changing the tumor microenvironment from having low immune activity to an active immune environment, ERNA-101 \"may not only lead to improved therapeutic outcomes as a monotherapy but is also anticipated to significantly enhance the efficacy of CAR-T and CAR-NK cell therapies in the future,\" the company said.</p><p>Regarding safety, body weight distribution showed no significant difference between the ERNA-101 and control groups, Eterna said.</p><p>Price: 0.4959, Change: +0.19, Percent Change: +60.49</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eterna Therapeutics Reports Positive Preclinical Results for Cancer Therapy ERNA-101; Shares Jump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEterna Therapeutics Reports Positive Preclinical Results for Cancer Therapy ERNA-101; Shares Jump\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-14 22:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Eterna <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (ERNA) shares nearly doubled in early trading on Tuesday after the company reported positive results from a preclinical study of its lead cell therapy product ERNA-101</p><p>Eterna said the proof-of-concept study demonstrated \"massive\" T cell infiltration after only one dose, with reduced tumor burden and extended survival in mice with ovarian cancer.</p><p>By changing the tumor microenvironment from having low immune activity to an active immune environment, ERNA-101 \"may not only lead to improved therapeutic outcomes as a monotherapy but is also anticipated to significantly enhance the efficacy of CAR-T and CAR-NK cell therapies in the future,\" the company said.</p><p>Regarding safety, body weight distribution showed no significant difference between the ERNA-101 and control groups, Eterna said.</p><p>Price: 0.4959, Change: +0.19, Percent Change: +60.49</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2503571945","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503571945","pubTimestamp":1736866012,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Eterna Therapeutics'  shares nearly doubled in early trading on Tuesday after the company reported positive results from a preclinical study of its lead cell therapy product ERNA-101Eterna said the proof-of-concept study demonstrated \"massive\" T cell infiltration after only one dose, with reduced tumor burden and extended survival in mice with ovarian cancer.By changing the tumor microenvironment from having low immune activity to an active immune environment, ERNA-101 \"may not only lead to improved therapeutic outcomes as a monotherapy but is also anticipated to significantly enhance the efficacy of CAR-T and CAR-NK cell therapies in the future,\" the company said.Regarding safety, body weight distribution showed no significant difference between the ERNA-101 and control groups, Eterna said.Price: 0.4959, Change: +0.19, Percent Change: +60.49","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ERNA":"Eterna Therapeutics Inc."},"translate_title":"Eterna Therapeutics报告癌症疗法ERNA-101的积极临床前结果；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERNA":1},"content_text":"Eterna Therapeutics' (ERNA) shares nearly doubled in early trading on Tuesday after the company reported positive results from a preclinical study of its lead cell therapy product ERNA-101Eterna said the proof-of-concept study demonstrated \"massive\" T cell infiltration after only one dose, with reduced tumor burden and extended survival in mice with ovarian cancer.By changing the tumor microenvironment from having low immune activity to an active immune environment, ERNA-101 \"may not only lead to improved therapeutic outcomes as a monotherapy but is also anticipated to significantly enhance the efficacy of CAR-T and CAR-NK cell therapies in the future,\" the company said.Regarding safety, body weight distribution showed no significant difference between the ERNA-101 and control groups, Eterna said.Price: 0.4959, Change: +0.19, Percent Change: +60.49","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}